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A b s t r A c t
Over the recent years, new oral anticoagulant agents have been developed and entered 
the clinical arena, the direct or non-vtamin K oral anticoagulants (NOACs). Although 
more expensive, these agents have been proven as equivalent or superior to vitamin 
K antagonists in the treatment of non-valvular atrial fibrillation (AF) and venous 
thrombo-embolism with a lower incidence of intracerebral hemorrhage. Nevertheless, 
occurrence of major or life-threatening bleeding events is still quite possible. Thus, 
there is a major concern regarding the lack of a specific antidote and rapid reversal 
agent in such disastrous situations. Fortunately, the development of effective specific 
NOAC antidotes has recently made great advances, which are herein briefly reviewed.
I N t r O D U c t I O N
Over the recent years, new classes of oral anticoagulant agents have been developed 
and entered into the clinical arena, the direct or non-vtamin K oral anticoagulants 
(NOACs). These agents belong to two classes, the direct thrombin inhibitor, dabigatran 
(the -gatrans), and the factor Xa inhibitors, such as rivaroxaban, apixan, edoxaban and 
betrixaban (the -xabans).1-4 These agents have been proven as equivalent or superior to 
vitamin K antagonists (VKAs) in the treatment of non-valvular atrial fibrillation (AF) 
and venous thrombo-embolism (VTE),4-6 albeit at an upfront increased cost. NOACs 
confer equivalent or better protection from thromboembolic events in these patient 
groups with lessened occurrence of intracerebral hemorrhage. However, there still re-
mains, albeit decreased, a possibility of such a disastrous cerebral bleeding event, while 
an increased risk of other site bleeding or major bleeding events has been reported.7 
Thus, there is a major concern regarding the lack of a specific antidote and rapid 
reversal agent in case of emergence of a life-threatening bleeding event. The shorter 
half-life of these agents, and hence a quicker dissipation of their anticoagulant effect, 
is not always entirely reassuring, particularly in emergency and menacing situations. 
The risk of hemorrhage-related mortality associated with NOACs in patients 
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requiring long-term anticoagulation was evaluated by a sys-
tematic review and meta-analysis of 11 studies (5 on AF and 
6 on VTE) comprising a total of 100,324 patients receiving 
rivaroxaban (4 studies), dabigatran (3 studies), apixaban (2 
studies) and edoxaban (2 studies).8 NOAC-treated patients 
had a 47% odds reduction compared with VKA (OR 0.53) 
and 64% odds reduction compared with low-molecular weight 
heparin–VKA (OR 0.36) regarding fatal bleeding risk. Case 
fatality due to major bleeding was lower in NOAC-treated 
patients both in AF (OR 0.68) and VTE (OR 0.54) patients. 
AF survivors of major bleeding events treated with NOACs 
had lower mortality compared with patients treated with VKAs 
(OR 0.57). The authors concluded that NOACs decrease the 
mortality risk related to major bleeding events, particularly 
in AF patients. Similarly, another meta-analysis of 13 rand-
omized controlled trials involving 102,707 patients receiving 
NOACs for the treatment of VTE or prevention of stroke/
systemic embolism due to non-valvular AF compared with 
warfarin or other VKAs administered to a target INR between 
2.0 - 3.0, indicated that the case-fatality rate of major bleeding 
was 7.57% in patients taking NOACs vs 11.04% in patients 
taking VKAs.5 When compared with warfarin, NOACs were 
associated with significant reductions in fatal bleeding (rela-
tive risk-RR, 0.53), cardiovascular mortality (RR, 0.88) and 
all-cause mortality (RR, 0.91). 
Nevertheless, the need for a drug-specific antidote with 
rapid reversal properties remains dire despite these encourag-
ing results, particularly when urgent surgery with a high hemor-
rhagic risk is needed or in cases of intracerebral hemorrhage or 
serious bleeding in another critical organ, or even in cases of 
accidental overdose, where the effect of anticoagulant therapy 
should be promptly reversed. Fortunately, the development 
of effective specific NOAC antidotes has recently made great 
advances,9-13 which are herein briefly reviewed.
r I s K  O F  M A J O r  b L E E D I N G  W I t H  
N O N - V I t A M I N  K  
O r A L  A N t I c O A G U L A N t s
According with the original studies of each NOAC, the 
risk of major bleeding is not negligible. In the RE-LY trial, 
the rate of major bleeding was 2.71% per year in the group 
receiving 110 mg of dabigatran and 3.11% per year in the 
group receiving 150 mg of dabigatran.14 A higher rate of ma-
jor bleeding with dabigatran 150 mg twice daily (3.74%) in 
comparison with 110 mg (2.99%) was further confirmed in the 
Long-term Multicenter Extension of Dabigatran Treatment in 
Patients with Atrial Fibrillation (RELY-ABLE) trial (hazard 
ratio 1.26).15 In the ROCKET trial, rate of major bleeding 
with rivaroxaban was 3.6% (similar to warfarin group, 3.4%), 
rate of intracranial hemorrhage was 0.5% (significantly lower 
compared with warfarin, 0.7% per year; hazard ratio, 0.67; 
P=0.02).16 However, major gastrointestinal (GI) bleeding was 
more common in the rivaroxaban group (3.2% as compared 
with 2.2% in the warfarin group; P<0.001). A subanalysis of 
the same trial indicated that a significantly higher rate of major 
or nonmajor clinical GI bleeding was encountered in rivaroxa-
ban- vs warfarin-treated patients (3.61 events/100 patient-years 
vs. 2.60 events/100 patient-years; hazard ratio: 1.42).17 In the 
ARISTOTLE trial, major bleeding was observed in 2.13% per 
year in the apixaban group, with fatal bleeding (including fatal 
hemorrhagic stroke) occurring in 34 patients.18,19 In the ADOPT 
trial, among 4495 acutely ill patients with cardiac or respiratory 
failure and/or other medical disorders and risk factors for VTE, 
receiving thromboprophylaxis with apixaban or subcutaneous 
enoxaparin, by day 30 major bleeding had occurred in 0.47% 
of patients in the apixaban group and in 0.19% of patients in 
the enoxaparin group (relative risk, 2.58; P=0.04).20 In the 
ENGAGE-AF TIMI 48 trail, the annualized rate of major 
bleeding was 2.75% with high-dose (60 mg) edoxaban and 
1.61% with low-dose (30 mg) edoxaban.21 The annualized rate 
of major GI bleeding was higher with high-dose edoxaban than 
with warfarin (1.51% vs. 1.23%), but the rate was lowest with 
low-dose edoxaban (0.82%). In the Explore-Xa trial, major or 
clinically relevant non-major bleeding was assessed among 508 
AF patients randomized to one of 3 doses (40, 60, or 80 mg 
once daily) of betrixaban (another factor Xa inhibitor mostly 
excreted unchanged in the bile) or unblinded warfarin.22 Over 
a mean of ~5 months, the rate of bleeding was lowest on be-
trixaban 40 mg (1 event); rates of bleeding with betrixaban 60 
or 80 mg were similar to those of warfarin (5, 5 and 7 events). 
According to a meta-analysis of all 71,683 participants 
included in the RE-LY, ROCKET AF, ARISTOTLE, and 
ENGAGE AF-TIMI 48 trials, NOACs significantly reduced 
stroke or systemic embolic events by 19% compared with war-
farin (relative risk - RR 0.81; p<0.0001), mainly driven by a 
reduction in hemorrhagic stroke (RR 0.49; p<0.0001), as well 
as all-cause mortality (RR 0.90; p=0.0003) and intracranial 
hemorrhage (0.48; p<0.0001), but had similar major bleed-
ing as with warfarin, and increased GI bleeding (RR 1.25; 
p=0.04).6 Another meta-analysis of 50 trials including 155,537 
patients, showed that the risk of major bleeding with NOACs 
varies with their indication for use.23 Significantly higher major 
bleeding was noted after hip surgery (odds ratio – OR 1.43), 
in patients with acute coronary syndrome (compared against 
placebo) (OR 2.89), and for medically ill patients (OR 2.79). 
Less bleeding was observed with treatment of acute venous 
thromboembolism or pulmonary embolism (OR 0.63). No sig-
nificant difference in bleeding was found during treatment of 
AF and for extended treatment of venous thromboembolism. 
Although a lower rate of hemorrhagic stroke has been 
consistently reported with use of NOACS,6,24 admittedly, it 
also appears that the rate of major GI bleeding related to the 
use of at least some NOACs is higher than that reported in 
warfarin users.25,26 In general, any major bleeding during oral 
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anticoagulant treatment is associated with a substantially in-
creased subsequent risk of both death and of thrombotic events 
such as ischemic stroke or myocardial infarction, especially 
following intracranial hemorrhage, and this risk is similarly 
elevated regardless of treatment with a NOAC or warfarin.27 
Of course, concomitant use of antiplatelet drugs clearly 
increase the risk for major bleeding.28 Other factors increasing 
the risk of major bleeding with NOACs may comprise older 
age, history of smoking, history of prior GI bleeding, mild ane-
mia, renal insufficeiency, baseline diastolic blood pressure ≥90 
mm Hg, history of chronic obstructive pulmonary disease, and 
prior use of aspirin; while female gender and diastolic blood 
pressure <90 mm Hg were associated with a decreased risk.29 
The effect of older age was confirmed by another subanalysis 
of the ROCKET AF trial: although efficacy and safety of rivar-
oxaban relative to warfarin did not differ with age (supporting 
rivaroxaban as an alternative for the elderly), elderly patients 
had higher major bleeding rates than younger patients (4.63% 
vs 2.74%/100 patient-years; P<0.0001).30 In another subanaly-
sis, independent clinical factors most strongly associated with 
GI bleeding were baseline anemia, history of GI bleeding, and 
long-term aspirin use.17 Although both ischemic stroke and 
bleeding outcomes have been correlated with plasma drug 
(dabigatran) concentrations (trough levels),31 monitoring of 
anticoagulation does not appear to be practical neither with 
this approach, nor with another method (thrombelastography) 
that has been suggested.32
M A N A G I N G  b L E E D I N G  W I t H  N O A c s
Although NOACs generally seem to confer a lower 
bleeding risk compared to VKAs, management of bleeding 
in patients on NOACs is challenging because there is lack of 
reliable and readily available laboratory tests of monitoring the 
anticoagulant effect of NOACs and therapeutic options are few 
and nonspecific and mostly supportive.33 Until now there have 
been several proposals with supportive and other nonspecific 
measures put forth by working groups and societies to manage 
such situations until specific and validated antidotes become 
available.1,34 These proposed actions included postponing or 
delaying the procedure, if at all possible, and monitoring the 
drug concentration for cases in need for urgent surgery, or if 
the dosage was not immediately available, propositions were 
based on laboratory tests, such as prothrombin time (PT) and 
activated partial thromboplastin time (aPTT), or measuring 
the anti-Xa activity; otherwise, supportive measures were rec-
ommended to be followed, while keeping procoagulant drugs 
at standby to use if and when abnormal intra- or post-operative 
bleeding occurred. In cases of bleeding, volume expansion 
and local hemostatic measures, blood transfusion, as needed, 
and fresh frozen plasma and off-label use of a non-specific 
pro-coagulant agent were empirically recommended, such as 
non-activated or activated prothrombin complex concentrates 
(PCC), or recombinant human factor VIIa, with its attendant 
shortcomings.35,36 In the case of dabigatran, hemodialysis could 
also be considered. In patients presenting within 2-6 hours of 
a suspected overdose with either dabigatran or apixaban, the 
use of activated charcoal may be a reasonable option.35
According with data from the ROCKET AF trial, during a 
median follow-up of 1.9 years, 779 (5.5%) patients experienced 
major bleeding at a rate of 3.52 events/100 patient-years with 
a similar event rate in each arm (n=395 for rivaroxaban and 
n=384 for warfarin).37 The median number of transfused red 
packed cells per episode was similar in both arms (2 units). 
Overall, few transfusions of whole blood (n=14), platelets 
(n=10), or cryoprecipitate (n=2) were used. Transfusion of 
fresh frozen plasma was significantly less in the rivaroxaban 
arm (n=45 vs n=81 units; odds ratio - OR 0.43; P <0.0001). 
Prothrombin complex concentrates (PCC) were administered 
less in the rivaroxaban arm (n=4 vs n=9). Outcomes after 
major bleeding were similar in the two groups. The authors 
concluded that among high-risk patients with AF who experi-
enced major bleeding in ROCKET AF, the use of fresh frozen 
plasma and PCC was less among those allocated rivaroxaban 
compared with warfarin; however, use of blood transfusion 
and outcomes after bleeding were similar.
Of course, a most dreaded complication with any antico-
agulant is intracranial hemorrhage. According to a study of 
55 patients on NOACs who developed this complication, the 
30-day mortality rate was 20%.38 Neurosurgical procedures 
were carried out in 37 patients (67%). Renal function was 
significantly lower in non-survivors. Pro-hemostatic therapy 
with PCC had no effect. The authors concluded that successful 
neurosurgical management of patients with intracranial hemor-
rhage and NOAC intake was feasible, but drastic deterioration 
was observed in some patients, particularly when impaired renal 
function was present, findings which underscore the urgent 
need of improving treatment modalities for these patients.38
Several groups have attempted to provide practical guid-
ance for the use of NOACs, either in the form of advice given in 
reviews and tabular data or proposing checklists, in an attempt 
to help optimize the risk-benefit ratio of NOAC therapy.1,3,4,39 
A European Heart Rhythm Association group has listed 15 
topics of specific clinical scenarios and formulated as practical 
answers as possible based on available evidence.1 A Canadian 
group proposed an evidence-based point-of-care tool—a 
1-page NOAC ABCD checklist available online: A (adher-
ence), B (bleeding), C (creatinine clearance), D (drug interac-
tions), E (examination), and F (follow-up).39 The checklist is 
accompanied by quick-reference tables summarizing dosing, 
interactions, and periprocedural management. However, when 
all these safe-keeping proposals have failed and one is faced 
with a threatening situation like major bleeding, a contingency 
plan with effective reversal strategies should be in place.33-36 
This can only be complete with the availability of specific 
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antidotes, which are now fortunately becoming available,10,12,13 
as detailed in the next section.
A N t I D O t E s  ( t A b L E  1 )
Idarucizumab (Praxbind®), a humanized antibody frag-
ment, is a specific antidote for dabigatran, developed by 
Boehringer Ingelheim.9,40 This is the first antidote of NOAC to 
receive approval by the FDA (October 16, 2015) (http://www.
fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm467300.htm) and the European Medicines Agency (EMA) 
(November 20, 2015) (http://www.ema.europa.eu/ema/index.
jsp?curl=pages/medicines/human/medicines/003986/hu-
man_med_001938.jsp&mid=WC0b01ac058001d124). This 
molecule binds to dabigatran with an affinity about 350 times 
greater than thrombin, preventing it from binding to thrombin 
and thus cancelling its anticoagulant effect.41 Idarucizumab 
is specific for dabigatran and does not bind thrombin or its 
substrates, nor does it activate platelets. In animal and human 
studies, idarucizumab did not promote or reduce thrombin 
generation, thus it has no intrinsic anticoagulant or proco-
agulant effects.
In a porcine trauma model, idarucizumab reduced dabi-
gatran-associated bleeding and mortality.42 It stopped bleed-
ing within 15 minutes and was associated with an immediate 
decrease in dabigatran anticoagulant effects. There was no 
evidence of safety concerns associated with the administration 
of idarucizumab. 
In a phase 1 randomized, placebo-controlled, double-
blind study, comprising 47 healthy volunteers (aged 18–45 
years) who received dabigatran 220 mg bid for 3 days and a 
final dose on day 4, and then idarucizumab (1 g, 2 g, or 4 g 
5-min infusion, or 5 g plus 2·5 g in two 5-min infusions given 
1 h apart) administered (each dose to 12 men) about 2 hours 
after the final dabigatran dose, idarucizumab immediately 
and completely reversed dabigatran-induced anticoagulation 
in a dose-dependent manner.43 Drug-related adverse events 
were all of mild intensity and reported in 7 participants (1 
infusion site erythema and hot flushes, 2 epistaxis, 1 infusion 
site hematoma, and 3 hematuria). No serious or severe adverse 
events were reported, no adverse event led to discontinuation 
of treatment, and no clinically relevant difference in incidence 
of adverse events was noted among treatment groups. 
A Phase 3 prospective cohort study, the RE-VERSE AD 
(A Study of the Reversal Effects of Idarucizumab on Active 
Dabigatran), was conducted to determine the safety of 5 g of 
IV idarucizumab and its capacity to reverse the anticoagulant 
effects of dabigatran in patients who had serious bleeding 
(group A) or required an urgent procedure (group B). Ac-
cording to an interim analysis of 90 patients who received 
idarucizumab (51 patients in group A and 39 in group B),12 
among 68 patients with an elevated dilute thrombin time 
test and 81 with an elevated ecarin clotting time at baseline, 
reversal was 100%. Idarucizumab normalized the test results 
within minutes in 88-98% of the patients. Concentrations of 
unbound dabigatran remained low (<20 ng/ml) at 24 hours 
in 79% of the patients. Among 35 assessed patients in group 
A, hemostasis was restored at a median of 11.4 hours. Among 
36 patients in group B who underwent a procedure, normal 
intraoperative hemostasis was reported in 33, and mildly or 
moderately abnormal hemostasis in the other 3 patients. One 
thrombotic event occurred within 72 hours after idarucizumab 
administration in a patient in whom anticoagulants had not 
been reinitiated.
Idarucizumab is available as a ready-to-use solution of 
tAbLE 1. Antidotes for Non-Vitamin K Oral Anticoagulants (NOACs)
Antidote Idarucizumab (Praxbind®) Andexanet alfa Aripazine, ciraparantag (PEr977)
Manufacturer Boehringer Ingelheim Portola Pharmaceuticals Perosphere Inc.
Type humanized monoclonal antibody 
fragment (Fab)
recombinant human Factor Xa  
variant (decoy) (39 kDa)
small synthetic, cationic water-
soluble molecule (512 Da)
NOAC Dabigatran Oral Factor Xa inhibitors All NOACs
Cleared by Kidney ? ?
Dose 5 g: 2 doses of 2.5 g IV over 5-10 min 
at 15 min apart (2.5 g/50 ml vial)
400 / 800 mg IV (30 mg/min)  
followed by 2-h infusion of 4-8 mg/min
Lower does for apixaban / higher dose 
for rivaroxaban
100-300 mg IV
Half-life 47 min (initial / 10.3 h (terminal) 1 h Onset of action: 10 min 
Duration of action: 24 h
Studies REVERSE-AD ANNEXA-4 Phase 1 study
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50 mg/ml (two 2.5g/50-ml vials, kept in the refrigerator and 
having a 24-month shelf life) (see package insert: http://www.
accessdata.fda.gov/drugsatfda_docs/label/2015/761025lbl.
pdf). Before use, the unopened vials may be maintained at 
room temperature for up to 48 hours if they are stored in the 
original package to protect them from light or for up to 6 hours 
if exposed to light. A total IV dose of 5 g is administered as 
2 consecutive 2.5-g infusions over 5-10 minutes at ≤15 min 
apart, expected to reverse all of the available dabigatran (i.e., 
all unbound and protein-bound dabigatran and its active me-
tabolites).41 Drug plasma concentrations decline in a biphasic 
manner with a rapid, initial half-life of ≈45 minutes with only 
4% of the peak concentration remaining in plasma after 4 
hours. The drug is eliminated mainly renally. However, there 
should be no concern in patients with renal insufficiency, since 
these patients often have elevated dabigatran plasma con-
centrations, and thus the higher idarucizumab exposure may 
be advantageous. The drug normalizes dabigatran-induced 
prolongation of the dTT (dilute thrombin time), ECT (ecarin 
clotting time), aPTT (activated partial thromboplastin time), 
TT (thrombin time), and activated clotting time within minutes 
in a dose-dependent manner. If the dTT or ecarin-based as-
says are not available, the aPTT or TT can be used to monitor 
dabigatran reversal with idarucizumab. 
The short half-life of idarucizumab in patients with normal 
renal function allows resumption of dabigatran therapy within 
24 hours in order to avoid the potential risk of thrombosis, 
provided that hemostasis has been secured.41 The effect of 
idarucizumab is vey rapid and sustained for 12 hours, mean-
ing that surgery or other procedures can be started shortly 
after administration. A pre-procedural normal aPTT and TT 
confirms reversal of the anticoagulant effect. Post-procedurally 
and after adequate hemostasis is restored, in patients at high 
risk for bleeding, treatment can start with a low dose of an 
anticoagulant for thromboprophylaxis, and the dose can 
then be increased to a therapeutic level once the bleeding 
risk abates. Since idarucizumab is specific for dabigatran, 
the anticoagulant activity of other anticoagulants will not be 
affected. In patients with renal impairment, the half-life of 
idarucizumab is prolonged, hence reinitiation of dabigatran 
may need to be delayed or an alternative anticoagulant may 
need to be considered. 
Andexanet alfa is another antidote, in injectable form, 
recently developed by Portola Pharmaceuticals for factor Xa 
inhibitors. This recombinant protein is a modified form of 
factor Xa that is catalytically inactive but retains high-affinity 
binding to factor Xa inhibitors. In animal models, andexanet 
alfa reversed immediately and in a dose-dependent manner 
the anticoagulant effect of factor Xa inhibitors, restored he-
mostasis and reduced bleeding.9,44 In Phase 1 and 2 studies in 
healthy volunteers, the antidote reversed antifactor Xa activity 
in a dose-dependent manner and no thrombotic events were 
reported.9 In these studies, it was observed that anticoagula-
tion returned to pre-treatment levels within few hours after a 
bolus infusion of the antidote and therefore a constant infu-
sion of the drug is recommended to reverse anticoagulation 
for longer periods of time.
More recently the combined results of ANNEXA-A and 
ANNEXA-R trials were reported.13 These trials evaluated the 
efficacy and safety of andexanet for the reversal of anticoagula-
tion with apixaban or rivaroxaban in older healthy volunteers 
(mean age 58 years), who were given 5 mg of apixaban twice 
daily or 20 mg of rivaroxaban daily. Among the apixaban-
treated individuals, anti–factor Xa activity was reduced by 
94% among those who received an andexanet bolus (n=24), as 
compared with 21% among those who received placebo (n=9) 
(P<0.001), and unbound apixaban concentration was reduced 
by 9.3 ng/ml vs 1.9 ng/ml (P<0.001); thrombin generation was 
fully restored in 100% vs 11% of the participants (P<0.001) 
within 2 to 5 minutes. Among the rivaroxaban-treated individu-
als, anti–factor Xa activity was reduced by 92% among those 
who received an andexanet bolus (n=27), as compared with 
18% among those who received placebo (n=14) (P<0.001), 
and unbound rivaroxaban concentration was reduced by 23.4 
ng/ml vs 4.2 ng/ml (P<0.001); thrombin generation was fully 
restored in 96% vs 7% of the participants (P<0.001). These 
effects were sustained when andexanet was administered as a 
bolus plus an infusion. No serious adverse or thrombotic events 
were reported. Another study, the ANNEXA-E (Andexanet 
Alfa a Novel Antidote to the Anticoagulant Effects of FXA 
Inhibitors-Edoxaban), is going to assess the effect of this an-
tidote in patients receiving edoxaban. An ongoing trial (AN-
NEXA-4; NCT02329327) is evaluating the efficacy and safety 
of andexanet in patients (estimated to be enrolled: n=270) with 
factor Xa inhibitor–associated acute major bleeding (https://
clinicaltrials.gov/ct2/show/NCT02329327).13
Aripazine or ciraparantag or PER977, has been in-
troduced as a universal antidote binding and inhibiting all 
NOACs;10,11 however, it has so far only been studied in volun-
teers taking edoxaban and the mechanism of action remains 
unknown. Aripazine is a small, synthetic, water-soluble, 
cationic molecule developed by Perosphere Inc. that binds 
to unfractionated heparin, low-molecular-weight heparin, 
fondaparinux, dabigatran and to the new factor Xa inhibitors 
through hydrogen bonding and charge–charge interactions. 
Preliminary data are promising. The molecule effectively re-
verses bleeding associated with factor Xa inhibitors in animal 
models of external and internal bleeding. In addition, the 
results of the first human, Phase I study have been recently 
published. In this study, the effect of single IV doses of ari-
pazine (5-300 mg) administered alone and after a 60-mg oral 
dose of edoxaban was examined in 80 healthy persons.45 After 
edoxaban, the mean whole-blood clotting time increased by 
37% over the baseline value. In patients receiving a single IV 
dose of aripazine (100-300 mg) 3 hours after the administra-
tion of edoxaban, the whole-blood clotting time decreased to 
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within 10% above the baseline value in ≤10 minutes, whereas 
in patients receiving placebo, this occurred much later (12-
15 hours). The whole-blood clotting time remained within 
10% above or below the baseline value for 24 hours after the 
administration of a single dose of aripazine. Edoxaban antico-
agulation significantly reduced the mean fibrin-fiber diameter 
(determined by scanning electron micrographs of clots) relative 
to baseline, which was restored to normal 30 minutes after 
administration of aripazine; there was no evidence of proco-
agulant activity after administration of aripazine (assessed by 
measuring levels of d-dimer, prothrombin fragment 1.2, and 
tissue factor pathway inhibitor and by whole-blood clotting 
time). Potentially related adverse events were transient mild 
perioral and facial flushing and dysgeusia; one person reported 
a moderate headache. In addition, one person had a moderate 
muscle cramp and elevation in creatinine phosphokinase levels, 
events that were not considered to be related to aripazine. 
Thus, in this study, baseline hemostasis was restored from the 
anticoagulated state within 10-30 minutes after administration 
of 100-300 mg of aripazine and was sustained for 24 hours. 
Additional phase 2 clinical studies are ongoing.45
c O N c L U s I O N
Non-vitamin K oral anticoagulants have been proven 
equivalent or superior to VKAs in the treatment of non-valvu-
lar AF and VTE, conferring protection from thromboembolic 
events with lessened occurrence of intracerebral hemorrhage. 
However, occurrence of major or life-threatening bleeding 
events is still quite possible; it has even been suggested that 
the rate of GI or other site major bleeding related to the 
use of at least some NOACs is higher than that reported in 
warfarin users. Thus, there is a major concern regarding the 
lack of a specific antidote and rapid reversal agent in case of 
a life-threatening bleeding event. The quicker dissipation of 
the anticoagulant effect of these agents due to their shorter 
half-life is not always entirely reassuring, particularly when 
urgent surgery with a high hemorrhagic risk is needed or in 
cases of intracerebral hemorrhage or serious bleeding in an-
other critical organ, or even in cases of accidental overdose, 
where the effect of anticoagulant therapy should be promptly 
reversed. Fortunately, the development of effective specific 
NOAC antidotes has recently made great advances, with one 
having already gained FDA and EMA approval and another 
two agents already in the pipeline.
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